Form 4: UTHR COO Benkowitz Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO Michael Benkowitz completed the sale of 14,440 shares of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), completed the final transactions under a Rule 10b5-1 trading plan established on June 3, 2025.
• On February 23, 2026, Benkowitz exercised options to acquire 9,375 shares of common stock at an exercise price of $117.76 per share.
• Concurrently, he sold these 9,375 shares at a price of $472.126 per share. These shares were held indirectly by a trust where Benkowitz and his spouse are co-trustees.
• Additionally, on the same date, he exercised options to acquire 5,065 shares of common stock at an exercise price of $146.03 per share.
• These 5,065 shares were also sold at $472.126 per share. These shares were held indirectly by a trust for which Benkowitz has sole investment and voting power, with family members as beneficiaries.
• Following these transactions, Benkowitz directly owns 2,648 shares of Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, making it an expected part of executive compensation management.

Positives

• The executive realized significant gains by exercising options at lower prices ($117.76 and $146.03) and selling shares at a higher market price ($472.126).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived by some investors as a reduction in insider holdings, although this is mitigated by the pre-arranged 10b5-1 plan.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which solely reports past insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives to manage their equity holdings and diversify personal portfolios. These planned sales typically have less market impact than unplanned, opportunistic sales, as they are scheduled in advance and not necessarily indicative of management's immediate outlook on the company's prospects.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Rule 10b5-1 trading plans by executives, such as Michael Benkowitz, aligns with common corporate governance practices in the U.S. public markets.
• Many executives at comparable biotechnology and pharmaceutical companies, like Gilead Sciences (GILD) or Amgen (AMGN), utilize similar pre-arranged plans to manage their equity compensation, providing a defense against insider trading allegations by establishing a trading schedule when not in possession of material non-public information.

Related Party Transactions

• The transactions involved shares held in two separate trusts: one beneficially owned by the Reporting Person where he and his spouse are co-trustees, and another beneficially owned by the Reporting Person's family members where he has sole investment and voting power. These are considered related party transactions as they involve entities closely tied to the reporting insider.

Stakeholder Impact

• Shareholders: The sale of shares by a high-ranking executive could lead to a minor, short-term negative sentiment, though the 10b5-1 plan largely neutralizes this. The overall impact on the company's stock price is likely minimal given the pre-planned nature.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions executed under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their personal finances and equity compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Michael Benkowitz, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation, Beneficial Ownership